Foster BA - Search Results

1

Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.

Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP. Hurwitz AA, et al. Among authors: foster ba. Cancer Res. 2000 May 1;60(9):2444-8. Cancer Res. 2000. PMID: 10811122

2

Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.

Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Foster BA, et al. Cancer Res. 1997 Aug 15;57(16):3325-30. Cancer Res. 1997. PMID: 9269988

3

The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.

Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM. Kaplan PJ, et al. Among authors: foster ba. Cancer Res. 1999 May 1;59(9):2203-9. Cancer Res. 1999. PMID: 10232609

4

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

Kwon ED, Foster BA, Hurwitz AA, Madias C, Allison JP, Greenberg NM, Burg MB. Kwon ED, et al. Among authors: foster ba. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15074-9. doi: 10.1073/pnas.96.26.15074. Proc Natl Acad Sci U S A. 1999. PMID: 10611340 Free PMC article.

5

The TRAMP mouse as a model for prostate cancer.

Hurwitz AA, Foster BA, Allison JP, Greenberg NM, Kwon ED. Hurwitz AA, et al. Among authors: foster ba. Curr Protoc Immunol. 2001 Nov;Chapter 20:20.5.1-20.5.23. doi: 10.1002/0471142735.im2005s45. Curr Protoc Immunol. 2001. PMID: 18432778

6

Cooperation between ectopic FGFR1 and depression of FGFR2 in induction of prostatic intraepithelial neoplasia in the mouse prostate.

Jin C, McKeehan K, Guo W, Jauma S, Ittmann MM, Foster B, Greenberg NM, McKeehan WL, Wang F. Jin C, et al. Cancer Res. 2003 Dec 15;63(24):8784-90. Cancer Res. 2003. PMID: 14695195

7

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer.

Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM, Burg MB, Allison JP. Kwon ED, et al. Among authors: foster ba. Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8099-103. doi: 10.1073/pnas.94.15.8099. Proc Natl Acad Sci U S A. 1997. PMID: 9223321 Free PMC article.

8

Peptide growth factors and prostate cancer: new models, new opportunities.

Foster BA, Kaplan PJ, Greenberg NM. Foster BA, et al. Cancer Metastasis Rev. 1998-1999;17(4):317-24. doi: 10.1023/a:1006162410436. Cancer Metastasis Rev. 1998. PMID: 10453274 Review.

9

Adenovirus-mediated transfer of inducible caspases: a novel "death switch" gene therapeutic approach to prostate cancer.

Shariat SF, Desai S, Song W, Khan T, Zhao J, Nguyen C, Foster BA, Greenberg N, Spencer DM, Slawin KM. Shariat SF, et al. Among authors: foster ba. Cancer Res. 2001 Mar 15;61(6):2562-71. Cancer Res. 2001. PMID: 11289132

10

Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation.

Freeman KW, Gangula RD, Welm BE, Ozen M, Foster BA, Rosen JM, Ittmann M, Greenberg NM, Spencer DM. Freeman KW, et al. Among authors: foster ba. Cancer Res. 2003 Oct 1;63(19):6237-43. Cancer Res. 2003. PMID: 14559809

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

185 results

Search Page

Filters